Melanoma Mutation Profiling For Personalised Treatment
Funder
National Health and Medical Research Council
Funding Amount
$571,191.00
Summary
Melanoma is an aggressive skin cancer, and the leading cause of skin cancer related deaths. Disease spread is difficult to detect and extremely difficult to cure. This bleak clinical outcome is changing with the development of personalised therapies which include small molecule inhibitors to treat metastatic melanoma. Here we seek to identify the spectrum of mutations in patient tumours and circulating tumour cells for advanced personalised treatment.
Communication skills training for oncology health care professionals working with culturally and linguistically diverse patients. The project will develop and evaluate two novel training programs designed to equip health professionals to communicate with cancer patients from different cultures. It is expected that the programs will improve trainees’ ability to communicate in a culturally sensitive way.
Development Of A Comprehensive Model For Colorectal Cancer Risk Prediction
Funder
National Health and Medical Research Council
Funding Amount
$317,012.00
Summary
Bowel cancer is the second most common cause of cancer death in Australia. While the average lifetime risk is 1 in 20, this is a great difference in individual risks. Screening and early detection can prevent 90% of bowel cancer deaths. We need to know who is at high-risk and therefore can be targeted for screening. In this project, I will develop the first tool that can predict precisely an individual’s personal risk of bowel cancer.
Structural and pharmaceutical studies on a novel human protein, MIC-1. Cancer and obesity are two of the main health problems facing Australia, as reflected by the National Research Priority: Promoting and Maintaining Good Health. This project will develop new diagnostic tools for early cancer detection and prognosis using the protein, MIC-1. MIC-1 is responsible for cachexia, a wasting disorder responsible for 25% of cancer deaths, which has no effective therapy. MIC-1 and antibodies neutrali ....Structural and pharmaceutical studies on a novel human protein, MIC-1. Cancer and obesity are two of the main health problems facing Australia, as reflected by the National Research Priority: Promoting and Maintaining Good Health. This project will develop new diagnostic tools for early cancer detection and prognosis using the protein, MIC-1. MIC-1 is responsible for cachexia, a wasting disorder responsible for 25% of cancer deaths, which has no effective therapy. MIC-1 and antibodies neutralising MIC-1 may provide therapeutic agents to control cancer cachexia and severe obesity. The project will optimise these molecules for therapeutic uses. These diagnostic and therapeutic tools will form the basis of a spin-off company for commercialisation. Read moreRead less
Radiolabelled MMP binding agents for the identification, quantification, and targeting of MMPs in central nervous system (CNS) disorders and tumours. Cancer and diseases of the central nervous system (CNS) represent two of the major health challenges facing Australia because of the aging population. In order to address these challenges we need to develop methods for identifying tumours and CNS diseases using non-invasive technologies and at an early stage so that treatments can be applied when t ....Radiolabelled MMP binding agents for the identification, quantification, and targeting of MMPs in central nervous system (CNS) disorders and tumours. Cancer and diseases of the central nervous system (CNS) represent two of the major health challenges facing Australia because of the aging population. In order to address these challenges we need to develop methods for identifying tumours and CNS diseases using non-invasive technologies and at an early stage so that treatments can be applied when they are most likely to work. In this project, we are developing new radiolabelled compounds that will enable the imaging of tumours, tumour metastases and CNS diseases states.Read moreRead less
New methods to improve regional isotope therapy of liver tumours in cancer patients. The most common cause of death in cancer patients is secondary tumours in vital organs. Successful treatment of liver tumours with regional isotope therapy now offers improved survival rates. This project will research novel radiolabelled nanoparticles and advanced computer imaging algorithms to improve regional isotope therapy of liver tumours. It will provide better methods of objective assessment and manageme ....New methods to improve regional isotope therapy of liver tumours in cancer patients. The most common cause of death in cancer patients is secondary tumours in vital organs. Successful treatment of liver tumours with regional isotope therapy now offers improved survival rates. This project will research novel radiolabelled nanoparticles and advanced computer imaging algorithms to improve regional isotope therapy of liver tumours. It will provide better methods of objective assessment and management that can reduce risk and improve patient survival.Read moreRead less
Combining PI3K, CDK4/6 Pathway Inhibitors And Immunotherapies In Triple-negative Breast Cancer (TNBC): A Novel Therapy Combination
Funder
National Health and Medical Research Council
Funding Amount
$626,345.00
Summary
Triple-negative breast cancer (TNBC) has the worst prognosis of all breast cancer subtypes, classically affecting young women and characterized by a lack of effective therapies. We show that blocking both PI3K and CDK4/6 pathways together effectively reduces TNBC growth in mice and can enhance anti-tumour immune responses. We aim to understand how these drugs work together and if adding immunotherapy can improve responses. Our project could provide a new treatment approach for TNBC patients.
Reducing The Greatest Uncertainty In Radiotherapy.
Funder
National Health and Medical Research Council
Funding Amount
$594,197.00
Summary
The weakest link in radiotherapy is defining treatment volumes (contouring). Lack of accuracy and consistency in clinical trial contouring has been shown to result in reduced patient outcomes. Manual review of contouring is resource intensive, expensive and for advanced treatments unachievable in a timely fashion. We will assess an automated approach to contouring assessment using 4 clinical trial datasets, changing practice for future studies and enabling consistent assessment in the clinic.
Optimising Radiation Therapy Delivery For Cancer Patients Using Daily Image Guidance To Maximize Cure And Reduce Normal Tissue Side Effects
Funder
National Health and Medical Research Council
Funding Amount
$510,968.00
Summary
When using radiotherapy to kill tumours, the radiation beams need to be targeted at the tumour, plus a margin of error around it to ensure that it receives sufficient dose despite uncertainties in its exact location relative to reference points used for beam alignment. Advanced statistical modelling techniques applied to data collected from patients will be used to determine the optimal margin width for individual patients to maximise cancer cure while minimising normal tissue side effects.
DNA methylation-based diagnosis of cancer and identification of novel therapeutic targets. In our aging society, cancer represents a severe economic and quality-of-life threat. DNA methylation switches genes off, and recently, it was shown that defects in DNA methylation contribute to human diseases including cancer. This project will identify defects in DNA methylation associated with cancer. Identifying these defects will enable us to design non-invasive, early diagnostic tests for cancer on b ....DNA methylation-based diagnosis of cancer and identification of novel therapeutic targets. In our aging society, cancer represents a severe economic and quality-of-life threat. DNA methylation switches genes off, and recently, it was shown that defects in DNA methylation contribute to human diseases including cancer. This project will identify defects in DNA methylation associated with cancer. Identifying these defects will enable us to design non-invasive, early diagnostic tests for cancer on blood or bodily excretions, and to pursue novel therapeutic approaches for treating cancer. The expected outcomes would generate exports to markets in the USA and Europe and replace imports of drugs and technology to treat cancer.Read moreRead less